Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 11:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 236 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Study Drug: Metformin Clear all
Active, not recruiting Phase 2 Interventional

The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)

NCT04207944
View directory record Official record
Conditions
IPMN, IPMN, Pancreatic
Interventions
Sulindac 400 MG, Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
21 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 18, 2026, 11:13 PM EDT
Terminated Phase 4 Interventional Results available

Fatty Liver Study in Patients With Type II Diabetes

NCT02365233
View directory record Official record
Conditions
Type II Diabetes, Nonalcoholic Fatty Liver
Interventions
DPP4 inhibitor, Pioglitazone, Lantus insulin
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Sep 18, 2026, 11:13 PM EDT
Completed Phase 1 Interventional

Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers

NCT01490658
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
repaglinide, metformin, repaglinide and metformin combination tablet
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 18, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Results available

A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263

NCT01128621
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK1292263, GSK1292263 matching placebo, Sitagliptin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 15, 2017 · Synced Sep 18, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes

NCT03268005
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Faster-acting insulin aspart, Insulin aspart, Insulin degludec, Metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
64
States / cities
Concord, California • Fresno, California • Fullerton, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 18, 2026, 11:13 PM EDT
Terminated Phase 4 Interventional Results available

Oral Anti Diabetic Agents in the Hospital

NCT04416269
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM)
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 18, 2026, 11:13 PM EDT
Not listed Phase 4 Interventional

Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus

NCT04027023
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Diabetes mellitus Type 2 De-escalation treatment (DET)
Drug
Lead sponsor
Sciema UG
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 18, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Results available

Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes

NCT01933672
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PF-04937319 once-daily, PF-04937319 split-dose, Sitagliptin once-daily
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
8
States / cities
DeLand, Florida • South Miami, Florida • High Point, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Sep 18, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants

NCT06813924
View directory record Official record
Conditions
Healthy Volunteers Sickle Cell Disease, Thalassemia
Interventions
Etavopivat, Digoxin, Pitavastatin, Metformin, Midazolam, Rosuvastatin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 18, 2026, 11:13 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Study of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS

NCT02087826
View directory record Official record
Conditions
Genetics, Metabolism, Type 2 Diabetes
Interventions
Mixed Meal Tolerance Test, Metformin
Other · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
1,017 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 18, 2026, 11:13 PM EDT
Recruiting Phase 3 Interventional

Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome

NCT05819853
View directory record Official record
Conditions
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Obese
Interventions
Semaglutide Injectable Product (Wegovy and/or Ozempic)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 35 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 18, 2026, 11:13 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects

NCT00499707
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
rosiglitazone maleate/metformin hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
48
States / cities
Anniston, Alabama • Chandler, Arizona • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Sep 18, 2026, 11:13 PM EDT
Recruiting Early Phase 1 Interventional

Relying on Pharmacotherapy to Improve Motor Gains in Chronic Stroke Survivors

NCT07588932
View directory record Official record
Conditions
Stroke
Interventions
Telmisartan, Metformin, Cilostazol
Drug
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
21 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 18, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

NCT01798706
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lixisenatide (AVE0010), Placebo, Antidiabetic background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
70 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
La Jolla, California • Norwalk, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 18, 2026, 11:13 PM EDT
Completed Phase 2 Interventional

Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus

NCT02434744
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
KD026, Placebo, Metformin
Drug
Lead sponsor
Response Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • West Hills, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 18, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

NCT03169959
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR, 5 mg saxagliptin, 10 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2017 · Synced Sep 18, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)

NCT01126580
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Metformin, LY2189265, Placebo (oral), Placebo (subcutaneous)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
807 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
28
States / cities
Huntsville, Alabama • Phoenix, Arizona • Buena Park, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 18, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Results available

A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin

NCT02554877
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PF-06291874, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
32
States / cities
Anaheim, California • Los Angeles, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2017 · Synced Sep 18, 2026, 11:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Metformin to Augment Low Milk Supply (MALMS) Study

NCT02179788
View directory record Official record
Conditions
Low Milk Supply, Pre-diabetes, Insulin Resistance, Suppressed Lactation
Interventions
Standard care, Metformin, Placebo
Behavioral · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
20 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 18, 2026, 11:13 PM EDT
Completed Phase 1 Interventional

Reducing Antipsychotic-Induced Weight Gain in Children With Metformin

NCT01231074
View directory record Official record
Conditions
Obesity, Weight Gain, Psychotropic Induced Weight Gain
Interventions
Metformin
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
10 Years to 17 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 1, 2019 · Synced Sep 18, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Placebo-controlled Study to Evaluate Effects of E5555 on Renal Function Parameters and OCT2 Activity

NCT01241669
View directory record Official record
Conditions
Healthy Subjects
Interventions
E5555
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Sep 18, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

A Study in Adults With Type 2 Diabetes

NCT01421459
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2963016, Lantus, OAMs
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
28
States / cities
Montgomery, Alabama • Brooksville, Florida • Fort Lauderdale, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Sep 18, 2026, 11:13 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

NCT00760344
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
SYR-472, Placebo, Sitagliptin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
105
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 102 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Sep 18, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

NCT00327015
View directory record Official record
Conditions
Diabetes
Interventions
Saxagliptin, Metformin, Placebo, pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
47
States / cities
Concord, California • Encinitas, California • Orange, California + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Sep 18, 2026, 11:13 PM EDT